Combination of GHRH antagonists and
docetaxel shows experimental effectiveness for the treatment of triplenegative breast cancers.
Not exact matches
A large trial
showing that men with newly diagnosed, advanced prostate cancer lived ten months longer, on average, when they received
docetaxel chemotherapy along with standard hormone therapy
The researchers
showed that cabazitaxel worked better than
docetaxel in human prostate cancer cells lines that were resistant hormone treatment, both in terms of slowing cancer - cell growth and in its ability to kill cancer cells.
Results also
showed 27.7 percent of patients in the ADT plus
docetaxel arm had a decline in prostate specific antigen (PSA) to less than 0.2 ng / mL at 12 months compared with 16.8 percent for those taking ADT alone.
Results
showed an increased survival of 13.6 months for patients treated with ADT plus
docetaxel than with ADT alone.
Long - term follow - up of a large phase III study
showed that chemohormonal therapy involving
docetaxel added to androgen deprivation therapy (ADT) prolongs overall survival (OS) over ADT alone in metastatic hormone - sensitive prostate cancer (mHSPC) patients with high - volume disease.
The U.S. drug maker released a statement on Monday saying that its Keynote - 010 study, a randomized Phase two - third trial,
showed that patients who were taking two different doses of Keytruda (FDA - approved two mg / kg dose and treatment dose of 10 mg / kg given every three weeks) had longer survival compared to those who took
docetaxel, the drug widely used for non-small cell lung cancer (NSCLC).
The drug's manufacturer, Roche, said trials in these patients have
shown that giving pertuzumab in combination with the drugs trastuzumab (Herceptin) and
docetaxel could extend survival by nearly 16 months compared to standard treatment.